European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
31 Aug 2009

TRIANA Study: Primary angioplasty versus fibrinolysis in the very elderly 

Hot Line II

 

Topics: Acute Coronary Syndromes (ACS)
Session number: 1848-1849
Session title: Primary angioplasty versus fibrinolysis in the very elderly. The TRIANA Study
Authors: Bueno, Hector - Dudek, Dariusz

Read the press release



Presenter | see Discussant report

Hector Bueno

Play presentation webcast

Open presentation slides
Hector Bueno, FESC (Spain)

List of Authors:
Héctor Bueno, Joaquín J. Alonso, Amadeo Betriu, Angel Cequier, Eulogio J. Garcia, Magda Heras, Jose L. Lopez-Sendon, Carlos Macaya, Rosana Hernandez-Antolin, on behalf of the TRIANA investigators, Spanish Society of Cardiology, Madrid, Spain

Abstract:

BACKGROUND:
Primary angioplasty (PCI) is currently considered the preferred reperfusion therapy for STEMI. However, data on clinical outcomes comparing primary PCI vs. fibrinolysis in very old patients are scarce.

METHODS:
The TRIANA study (clinicaltrials.gov # NCT00257309) is a Spanish multicenter randomized trial comparing primary PCI versus a conservative strategy consisting in fibrinolysis (weight-adjusted TNK+UFH) and rescue PCI. Included patients were 75 years of age or older presenting within 6 hours after STEMI. Patients with accepted contraindications for fibrinolysis and those with any previous cerebrovascular event, cardiogenic shock or blood pressure >180/110 mmHg at any time during the event were excluded. The primary endpoint was the composite of all-cause death, recurrent myocardial infarction, or disabling stroke at 30 days. Secondary endpoints were recurrent ischemia leading to revascularization, and major bleeding. Events were adjudicated by an “ad hoc” committee blinded to the study treatments.

RESULTS:
The trial was prematurely stopped due to slow recruitment, after enrolling 266 out of the 560 planned patients. Mean age was 81 years and 56% men. The two treatment groups were well balanced with regard to demographic characteristics and risk factors.

Outcomes at 30 days were as follows. After one-year follow-up, results tended to equate.

CONCLUSIONS:
In spite of the sample size limitation, this trial shows a trend towards a lower mortality, reinfarction and disabling stroke in elderly patients undergoing primary PCI compared with fibrinolysis. In addition, recurrent ischemia is dramatically reduced by primary PCI. Therefore, this approach might also be recommended for the oldest patients presenting with STEMI.



Discussant | see Presenter abstract

Darius Dudek

Play presentation webcast

Open presentation slides
Dariusz Dudek, FESC (Poland)


Notes to editor
This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.